SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS) announced today the U.S. commercial launch of UCERIS™ (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. UCERIS was approved by the U.S. Food and Drug Administration on January 14, 2013. UCERIS contains budesonide, a locally acting glucocorticosteroid, in a novel oral tablet formulation that utilizes proprietary MMX® multi-matrix system colonic delivery technology. The approved dosing regimen for adult patients is one 9 mg tablet taken orally once daily in the morning for up to 8 weeks.